Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9567989 | 0.77 | PRMT5 (0.60) | PRMT5WDR77PSMB5CRBNTRPM8 | |
| SCHEMBL6493783 | 0.70 | GRM7 (0.42) | — | |
| SCHEMBL9568169 | 0.70 | PRMT5 (0.52) | PRMT5WDR77PSMB5MTNR1AMTNR1B | |
| SCHEMBL5161371 | 0.69 | MAPT (0.45) | MAPTPKM | |
| SCHEMBL9568009 | 0.67 | LMNA (0.56) | PRMT5WDR77PSMB5CRBNTRPM8 | |
| SCHEMBL7398455 | 0.67 | ALDH1A1 (0.57) | PRMT5WDR77PSMB5 | |
| SCHEMBL31613075 | 0.67 | PRMT5 (0.55) | PRMT5WDR77PSMB5CRBN | |
| SCHEMBL6493780 | 0.66 | MAPK1 (0.36) | CRBNMAPTPKM | |
| SCHEMBL10656464 | 0.65 | HTT (0.51) | PRMT5WDR77PSMB5CRBNHAO1 | |
| SCHEMBL9568003 | 0.64 | PRMT5 (0.47) | PRMT5WDR77PSMB5CRBNTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | PRMT5 3251/4885WDR77 3057/4885PSMB5 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.